000184948 000__ 01339mam\a2200325\a\4500
000184948 001__ 184948
000184948 005__ 20220217103649.0
000184948 008__ 870311s1986\\\\dcu\\\\\\b\\\f000\0\eng\c
000184948 010__ $$a   87600681
000184948 035__ $$a(OCoLC)ocm15094631
000184948 035__ $$9AAV3724SI
000184948 035__ $$a184948
000184948 040__ $$aDGPO/DLC$$cDLC$$dGPO
000184948 043__ $$an-us---
000184948 049__ $$aISEA
000184948 0500_ $$aKF27$$b.G664 1986a
000184948 074__ $$a1016-A, 1016-B (microfiche)
000184948 08200 $$a362.1/969792$$219
000184948 0860_ $$aY 4.G 74/7:D 84/20
000184948 1101_ $$aUnited States.$$bCongress.$$bHouse.$$bCommittee on Government Operations.$$bIntergovernmental Relations and Human Resources Subcommittee.
000184948 24510 $$aAIDS drug development and related issues :$$bhearing before a subcommittee of the Committee on Government Operations, House of Representatives, Ninety-ninth Congress, second session, July 1, 1986.
000184948 260__ $$aWashington :$$bU.S. G.P.O. :$$bFor sale by the Supt. of Docs., Congressional Sales Office, U.S. G.P.O.,$$c1986.
000184948 300__ $$aiii, 173 p. ;$$c24 cm.
000184948 500__ $$aDistributed to some depository libraries in microfiche.
000184948 500__ $$aShipping list no.: 87-16-P.
000184948 500__ $$aItem 1016-A, 1016-B (microfiche)
000184948 504__ $$aBibliography: p. 153.
000184948 650_0 $$aAIDS (Disease)$$xResearch$$zUnited States$$xFinance.
000184948 650_0 $$aAIDS (Disease)$$zUnited States$$xPrevention.
000184948 85230 $$bdfich$$hY 4.G 74/7:$$iD 84/20
000184948 909CO $$ooai:library.usi.edu:184948$$pGLOBAL_SET
000184948 948__ $$ac:mm
000184948 980__ $$aBIB
000184948 980__ $$aGOV RESOURCE